Ocugen IncNASDAQ:OCGN
- LAST PRICE1.6300
- TODAY'S CHANGE (%)0.0300 (1.8750%)
- Bid / Lots1.6200/ 31
- Ask / Lots1.6300/ 16
- Open / Previous Close1.6200 / 1.6000
- Day Range
- 52 Week Range
- Volume849,795
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OCGN |
|---|---|---|
| 09:32 ET | 163857 | 1.6299 |
| 09:34 ET | 14655 | 1.6291 |
| 09:36 ET | 59942 | 1.6375 |
| 09:38 ET | 25222 | 1.6345 |
| 09:39 ET | 33728 | 1.65 |
| 09:41 ET | 52811 | 1.65 |
| 09:43 ET | 43559 | 1.6586 |
| 09:45 ET | 38354 | 1.648 |
| 09:48 ET | 60748 | 1.6399 |
| 09:50 ET | 72290 | 1.64 |
| 09:52 ET | 30036 | 1.63 |
| 09:54 ET | 108635 | 1.61 |
| 09:56 ET | 36379 | 1.6199 |
| 09:57 ET | 6540 | 1.63 |
| 09:59 ET | 9640 | 1.63 |
Today
Yesterday
OCGN FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm - OCGN, from 12 hours ago by Dow Jones
12 hours ago by Dow JonesOCGN DEADLINE ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm - OCGN, from 17 hours ago by Dow Jones
17 hours ago by Dow JonesSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN, from 22 hours ago by Dow Jones
22 hours ago by Dow JonesOCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, from 22 hours ago by Dow Jones
22 hours ago by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ocugen Inc | 465.8M | -6.9x | --- |
ALX Oncology Holdings Inc | 458.5M | -2.4x | --- |
IGM Biosciences Inc | 490.5M | -1.9x | --- |
Verve Therapeutics Inc | 448.4M | -1.8x | --- |
Absci Corp | 522.4M | -3.9x | --- |
Neurogene Inc | 486.4M | -8.1x | --- |
Company Information
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
Contact Information
- Headquarters
- 11 GREAT VALLEY PARKWAYMALVERN, PA, United States 19355
- Phone
- 484-328-4701
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer
- Shankar Musunuri
- Principal Financial Officer, Interim Chief Accounting Officer
- Michael Breininger
- Chief Marketing Officer
- Huma Qamar
- Chief Scientific Officer, Executive Officer
- Arun Upadhyay
- Independent Director
- Kirsten Castillo
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $465.8M |
|---|---|
Revenue (TTM) | $7.1M |
Shares Outstanding | 257.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 3.71 |
EPS | $-0.23 |
Book Value | $0.16 |
P/E Ratio | -6.9x |
Price/Sales (TTM) | 66.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -851.01% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
